A real-world, retrospective study of antifibrotic treatments (pirfenidone or nintedanib) in patients with acute exacerbation of idiopathic pulmonary fibrosis
Latest Information Update: 09 Aug 2021
At a glance
- Drugs Nintedanib (Primary) ; Pirfenidone (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- 09 Aug 2021 New trial record
- 26 Jul 2021 Results published in the Respiratory Medicine